HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Estee Lauder/Donna Karan

This article was originally published in The Rose Sheet

Executive Summary

Estee Lauder/Donna Karan: Licensing agreement giving Lauder exclusive worldwide rights to manufacture, distribute, market and sell beauty products under the Donna Karan New York and DKNY trademarks closed Nov. 10. Following a transition period, Estee Lauder will assume sales to retailers Feb. 1, Karan announced. Estee Lauder USA President and CEO Robin Burns will head the Donna Karan beauty division ("The Rose Sheet" Oct. 6, p. 5). In a Nov. 11 announcement, Donna Karan said it would eliminate 79 positions in its beauty division related to the spin off...

You may also be interested in...



Donna Karan Warms Fragrance Category With Black Cashmere

Donna Karan Cosmetics is introducing Black Cashmere women's fragrance in September to build upon the equity of its successful Cashmere Mist fragrance franchise, licensee Estee Lauder said

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Latest Headlines
See All
UsernamePublicRestriction

Register

RS004851

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel